ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.94935
0.03%
Brent Oil
84.125
0.70%
Bitcoin
57,806.37
-0.74%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) Noticias

EXEL Exelixis Inc

21.925
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:03
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Exelixis Inc EXEL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 21.925 03:00:03
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
21.925
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202415:05BWExelixis Announces First Quarter 2024 Financial Results and..
16/4/202415:05BWExelixis to Release First Quarter 2024 Financial Results on..
27/2/202417:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:05BWExelixis to Webcast Fireside Chats as Part of Investor..
23/2/202417:33EDGAR2Form 144 - Report of proposed sale of securities
22/2/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202418:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:19EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202415:49EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/2/202415:28EDGAR2Form 8-K - Current report
06/2/202415:05BWExelixis Announces Fourth Quarter and Fiscal Year 2023..
01/2/202415:05BWExelixis to Webcast Fireside Chats as Part of Investor..
25/1/202407:00BWExelixis Announces Detailed Results of Phase 3 CONTACT-02..
23/1/202415:05BWExelixis to Release Fourth Quarter and Fiscal Year 2023..
22/1/202416:00BWOpdivo® (nivolumab) in Combination with CABOMETYX®..
18/1/202415:05BWEuropean Patent Office Rules in Favor of Exelixis on..
16/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202420:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202420:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/1/202408:06EDGAR2Form 8-K - Current report
07/1/202415:00BWExelixis Announces Preliminary Fiscal Year 2023 Financial..
02/1/202415:05BWExelixis to Present at the 42nd Annual J.P. Morgan..
20/12/202315:20EDGAR2Form 8-K - Current report
14/12/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202318:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202315:56EDGAR2Form 144 - Report of proposed sale of securities
13/12/202315:27EDGAR2Form 144 - Report of proposed sale of securities
12/12/202315:26EDGAR2Form 144 - Report of proposed sale of securities
07/12/202315:05BWExelixis 2023 R&D Day: Science & Strategy to be Webcast on..
04/12/202317:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202307:02BWExelixis Announces Initiation of the STELLAR-305 Phase 2/3..
04/12/202307:00BWExelixis and Arcus Biosciences Announce Clinical Trial..
30/11/202315:10EDGAR2Form 144 - Report of proposed sale of securities
29/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202315:05BWExelixis to Present at the Piper Sandler 35th Annual..
20/11/202318:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/11/202308:00BWExelixis Announces Encouraging Results from Expansion Cohort..
09/11/202315:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
EXEL
Exelixis
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados